Please assess the completion status of the following clinical trial:

Trial Title: The Effect of Guanfacine on Delirium in Critically Ill Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion criteria~* Patients admitted to the UAB hospital Surgical Intensive Care Unit (SICU)~* 18 years of age or older~* Expected total ICU length of stay of 72 hours or more per treating physician~* Diagnosed with delirium based on CAM-ICU assessment (see attached CAM-ICU assessment form)~Exclusion Criteria~* Patients younger than 18 years old~* Expected discharge from ICU within 72 hours of admission~* Expected or inevitable death with 48 hours of enrollment~* Pregnancy or breast feeding~* Non-English speaking~* Patients unable to be assessed by CAM-ICU due to neurologic illness~* Altered consciousness unable to participate in CAM-ICU assessment~* Patients with previous diagnosis of chronic, acute, subacute neurologic disease, or neurodegenerative disease~* Mental illness and/or psychosis~* Acute alcohol withdrawal~* No enteral route available for administration~* Treating physician refusal of enrollment based on severe hypotension (defined as requiring a vasopressor for longer than 24 hours) or bradycardia (Hr\<50 bpm) at the time of screening~* Hepatic encephalopathy~* Blind or Hearing impaired~* Taking Guanfacine, for any reason~* On CYP3A inhibitor such as azole antifungals or clarithromycin~* On CYP3A inducers such as phenytoin or rifampin~* Severe xerostomia~* Enrolled in another interventional research trial

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): Placebo, lactulose monohydrate, encapsulated, once nightly at 2100, for up to 14 day study duration or otherwise indicated by study protocol.
- Guanfacine (Type: EXPERIMENTAL): Guanfacine immediate-release, 2mg dose, over-encapsulated tablet, once nightly at 2100, for up to 14 day study duration or otherwise indicated by study protocol.

Based on this trial design, predict the completion outcome and termination type (if applicable).